Arvinas draws Wedbush downgrade after data for Pfizer-partnered cancer drug
Arvinas (ARVN) stock faces a downgrade after underwhelming trial data for breast cancer drug vepdegestrant developed with ...
ARVN Stock Plunges 53% Following Mixed Data From Breast Cancer Study
Arvinas stock plummets 53% on mixed data from phase III metastatic breast cancer study on lead pipeline candidate, vepdegestrant.
Arvinas price target lowered to $20 from $82 at BMO Capital
BMO Capital analyst Etzer Darout lowered the firm’s price target on Arvinas (ARVN) to $20 from $82 and keeps an Outperform rating on the ...
PharmiWeb22 小时
Arvinas and Pfizer Announce Positive Topline Results from Phase 3 VERITAC-2 Clinical Trial
Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 VERITAC-2 clinical trial (NCT05654623) evaluating vepdegestrant monotherapy versus ...
Arvinas downgraded to Neutral from Outperform at Wedbush
Wedbush downgraded Arvinas (ARVN) to Neutral from Outperform with a price target of $12, down from $57.Optimize Your Investment Research with ...